BIOAGE LABS, INC. SHAREHOLDERS HAVE AN OPPORTUNITY TO RECOVER THEIR INVESTMENT LOSSES
BioAge Labs, Inc.
Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired BioAge Labs, Inc. (“BioAge” or the “Company”) (NASDAQ: BIOA) stock pursuant and/or traceable to the Company’s September 26, 2024’s initial public offering. The lawsuit seeks to recover BioAge shareholders’ investment losses.
If you purchased securities in BioAge pursuant and/or traceable to the Company’s September 26, 2024’s initial public offering, and would like to discuss your legal rights and/or options, please click “Join Class Action” above.
According to the lawsuit, BioAge made misrepresentations concerning its ongoing STRIDES Phase 2 clinical trial of azelaprag, its lead product candidate, in combination with GLP-1R agonists to establish proof of concept for enhanced weight.
If you wish to serve as lead plaintiff for the Class, you must file papers by March 10, 2025. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
ATTORNEY ADVERTISING. © 2025 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Peter Allocco
Investor Relations Manager
Bernstein Liebhard LLP
https://www.bernlieb.com
(212) 951-2030
pallocco@bernlieb.com
